ZANTAC 300 MG
RANITIDINE (RANITIDINE HYDROCHLORIDE) : 300 MG · DIN 02212358 · GLAXOSMITHKLINE INC
Health Canada status: CANCELLED POST MARKET
What is ZANTAC?
ZANTAC 300 MG contains RANITIDINE (RANITIDINE HYDROCHLORIDE) : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02212358, held by GLAXOSMITHKLINE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 14-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZANTAC used for?
ZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. These include the treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence; the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients; the prophylaxis of recurrent hemorrhage from bleeding ulcers; the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients. In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02212358 |
|---|---|
| Brand name | ZANTAC |
| Generic / active ingredient | RANITIDINE (RANITIDINE HYDROCHLORIDE) : 300 MG |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BA02 RANITIDINE |
| AHFS class | 56:28.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 14-Sep-2017 |
| Original market date | 1999-12-20 00:00:00 |
How is it stored and handled?
ZANTAC® Tablets: Store between 2°C and 30°C. Protect from light. ZANTAC® Injection: Store between 2°C and 25°C. Protect from light. ZANTAC® Injection should not be autoclaved.
How is it supplied?
ZANTAC® Tablets 150 mg: foil packs of 60 tablets and bottles of 100 and 500 tablets. ZANTAC® Tablets 300 mg: foil packs of 30 tablets and bottles of 60 tablets. ZANTAC® Injection: 2 mL unit dose colourless glass vials in packs of 10 and 40 mL multidose colourless glass vials in packs of 1.
What can be used instead?
Other Canadian products sharing ATC code A02BA02 RANITIDINE. 5 of 96 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAR-RANITIDINE | 150 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443708 |
| MAR-RANITIDINE | 300 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443716 |
| MAXIMUM STRENGTH ACID REDUCER WITHOUT PRESCRIPTION | 150 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02293471 |
| MINT-RANITIDINE | 150 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526379 |
| MINT-RANITIDINE | 300 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526387 |
| ACID REDUCER | 150 MG | TABLET | APOTEX INC | DORMANT | DIN 02296160 |
| ACID REDUCER | 150 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | APPROVED | DIN 02291282 |
| ACID REDUCER | 150 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02400103 |
| ACID REDUCER | 75 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02237829 |
| ACID REDUCER | 75 MG | TABLET | APOTEX INC | DORMANT | DIN 02230507 |
Who else supplies RANITIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RANITIDINE appears in 4061 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.